| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $1,133,592 | 11 | 100 |
| Jordan Julie | Chief Medical Officer | 0 | $0 | 1 | $18,128 | $-18,128 |
| McMinn Rachel | Chief Executive Officer | 0 | $0 | 1 | $73,995 | $-73,995 |
| Cobb Stuart | Chief Scientific Officer | 0 | $0 | 1 | $141,446 | $-141,446 |
| Cvijic Christine Mikail | President and CFO | 0 | $0 | 8 | $900,023 | $-900,023 |
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Over the last 12 months, insiders at Neurogene Inc. have bought $0 and sold $1.13M worth of Neurogene Inc. stock.
On average, over the past 5 years, insiders at Neurogene Inc. have bought $2.72M and sold $656,421 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 48,770 shares for transaction amount of $1.26M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2024‑11‑26.
| 2026-07-07 | Sale | Cvijic Christine Mikail | President and CFO | 4,200 0.0295% | $36.13 | $151,763 | -0.33% | |
| 2026-07-06 | Sale | Cvijic Christine Mikail | President and CFO | 600 0.0042% | $36.02 | $21,613 | +12.65% | |
| 2026-07-02 | Sale | Cvijic Christine Mikail | President and CFO | 4,061 0.0264% | $34.82 | $141,417 | +3.79% | |
| 2026-07-01 | Sale | Cvijic Christine Mikail | President and CFO | 739 0.0047% | $34.06 | $25,170 | +8.12% | |
| 2026-05-06 | Sale | Cvijic Christine Mikail | President and CFO | 9,600 0.0594% | $31.25 | $300,043 | +4.02% | |
| 2026-03-26 | Sale | McMinn Rachel | Chief Executive Officer | 3,352 0.0223% | $22.07 | $73,995 | +46.03% | |
| 2026-03-26 | Sale | Cvijic Christine Mikail | President and CFO | 2,558 0.0167% | $21.62 | $55,316 | +46.03% | |
| 2026-03-26 | Sale | Jordan Julie | Chief Medical Officer | 828 0.0055% | $21.89 | $18,128 | +46.03% | |
| 2026-03-13 | Sale | Cvijic Christine Mikail | President and CFO | 4,045 0.0253% | $20.81 | $84,176 | +43.10% | |
| 2026-03-13 | Sale | Cobb Stuart | Chief Scientific Officer | 6,797 0.0425% | $20.81 | $141,446 | +43.10% | |
| 2026-02-27 | Sale | Cvijic Christine Mikail | President and CFO | 4,800 0.0331% | $25.11 | $120,526 | +24.95% | |
| 2025-05-14 | Sale | Cobb Stuart | Chief Scientific Officer | 6,797 0.0475% | $15.15 | $103,003 | +34.30% | |
| 2025-03-13 | Sale | Cvijic Christine Mikail | President and CFO | 4,501 0.0216% | $16.94 | $76,247 | +16.73% | |
| 2024-11-26 | Samsara BioCapital GP, LLC | 10 percent owner | 48,770 0.3334% | $25.83 | $1.26M | -27.39% | ||
| 2024-11-22 | McMinn Rachel | Chief Executive Officer | 47,500 0.2565% | $20.40 | $969,000 | -3.94% | ||
| 2024-11-22 | Cvijic Christine Mikail | President and CFO | 24,000 0.1301% | $20.48 | $491,400 | -3.94% |
| McMinn Rachel | Chief Executive Officer | 1344307 8.507% | $51.89M | 1 | 1 | <0.0001% |
| Cvijic Christine Mikail | President and CFO | 84040 0.5318% | $3.24M | 1 | 9 | <0.0001% |
| Cobb Stuart | Chief Scientific Officer | 30497 0.193% | $1.18M | 0 | 2 | |
| Jordan Julie | Chief Medical Officer | 12472 0.0789% | $481,419.20 | 0 | 1 | |
| Samsara BioCapital GP, LLC | 10 percent owner | 1717127 10.8663% | $66.28M | 1 | 0 | <0.0001% |
$3,611,891 | 113 | 13.40% | $661.35M | |
$9,654,532 | 101 | -5.65% | $649.88M | |
$24,384,691 | 42 | -30.27% | $665.1M | |
$31,271,604 | 28 | 28.69% | $540.6M | |
$8,866,498 | 28 | 33.64% | $666.13M | |
$112,238,340 | 19 | 39.16% | $514.11M | |
$129,396,927 | 18 | 48.82% | $668.28M | |
$133,809,976 | 13 | 31.29% | $605.85M | |
$6,385,840 | 12 | 0.69% | $627.73M | |
$130,748,265 | 10 | 53.98% | $613.63M | |
$75,069,528 | 10 | 19.77% | $675.87M | |
$62,616,785 | 8 | -7.00% | $580.23M | |
$5,529,561 | 8 | 5.30% | $522.59M | |
$13,043,783 | 8 | 732.82% | $565.8M | |
$21,792,890 | 6 | 75.72% | $558.08M | |
$4,745,999 | 5 | -4.91% | $591.84M | |
$164,999,952 | 5 | -44.44% | $547.08M | |
$7,234,370 | 3 | -3.34% | $637.73M | |
Neurogene Inc. (NGNE) | $2,720,023 | 3 | -11.76% | $609.97M |
| Increased Positions | 40 | +40.4% | 2M | +14.25% |
| Decreased Positions | 37 | -37.37% | 976,919 | -6.39% |
| New Positions | 16 | New | 2M | New |
| Sold Out Positions | 8 | Sold Out | 312,009 | Sold Out |
| Total Postitions | 102 | +3.03% | 17M | +7.87% |
| Samsara Biocapital, Llc | $34,617.00 | 11.45% | 1.72M | 0 | 0% | 2025-09-30 |
| Rtw Investments, Lp | $27,467.00 | 9.08% | 1.36M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $26,188.00 | 8.66% | 1.3M | +22,346 | +1.75% | 2025-09-30 |
| Casdin Capital, Llc | $26,114.00 | 8.64% | 1.3M | 0 | 0% | 2025-09-30 |
| Ecor1 Capital, Llc | $25,630.00 | 8.48% | 1.27M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $19,992.00 | 6.61% | 991,691 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $19,174.00 | 6.34% | 951,100 | -26,582 | -2.72% | 2025-09-30 |
| Balyasny Asset Management L.P. | $14,092.00 | 4.66% | 699,002 | +699,002 | New | 2025-09-30 |
| Toronto Dominion Bank | $13,736.00 | 4.54% | 681,337 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $12,189.00 | 4.03% | 604,611 | -5,726 | -0.94% | 2025-09-30 |